Siemens Shares Stagnate Despite Record Operational Performance

Siemens AG is delivering a series of operational records as it begins its new fiscal year. However, investors have so far declined to reward this fundamental strength with share price gains. A profound strategic shift is instead fostering noticeable market caution, overshadowing the company’s robust order books and sales growth.

The Munich-based industrial giant reported an order backlog of €120 billion, setting a new record. Revenue for the first quarter climbed by eight percent. Despite these strong indicators, expectations of a share price rally have been disappointed. The stock recently declined, closing at €218.80 on Friday. This movement also saw the price fall below the closely watched 200-day moving average, which currently stands at approximately €235.

Strategic Overhaul and Investor Uncertainty

The primary driver behind this divergence between strong fundamentals and weak market performance is the planned separation of the medical technology subsidiary, Siemens Healthineers. The parent company intends to relinquish its controlling majority stake and distribute shares directly to Siemens shareholders. With concrete details regarding the timeline and tax implications not scheduled for announcement until early in the second quarter, investors currently find it difficult to calculate the impact on per-share earnings and dividends.

This period of strategic uncertainty is compounded by a leadership transition; Veronika Bienert is set to take over as the new Chief Financial Officer on April 1.

Should investors sell immediately? Or is it worth buying Siemens?

To sharpen its future strategic focus exclusively on industry and infrastructure, management is concurrently advancing a comprehensive digitalization initiative. Recent strategic developments include:

• U.S. Department of Energy: A statement of intent to modernize American scientific infrastructure using industrial artificial intelligence.
• NVIDIA Partnership: Development of fully AI-controlled manufacturing facilities, commencing in 2026 at the Electronics Factory in Erlangen.
• Altair Engineering: Ongoing integration of this U.S. software provider to strengthen the high-margin digital business segment.

In a move to counter the technical share price weakness in the interim, the company is deploying significant capital. An accelerated share buyback program led to the repurchase of 18 million of its own shares in March alone, a measure that provides arithmetic support for future earnings per share.

Key Clarifications Expected in May

The tension between excellent core operational performance and unresolved strategic questions is likely to be resolved in the near term. The group will present its second-quarter results on May 13. Market participants expect, by this date at the latest, the missing details regarding the Healthineers transaction. This information is seen as crucial for a reassessment of the future earning power of the streamlined industrial conglomerate.